Parkinson’s disease psychosis drug gets favorable review from FDA advisory panel

The lack of available treatments that adequately treat Parkinson’s disease psychosis proved to be a big motivating factor for a majority of members of the Food and Drug Administration’s...

Source: Clinical Neurology News - March 29, 2016 Category: Neurology Source Type: news